U.S. Real Estate Stock News

OTCPK:KBSR
OTCPK:KBSROffice REITs

KBS Real Estate Investment Trust III (OTCPK:KBSR) FFO Loss Reinforces Bearish Narratives On Cash Generation

KBS Real Estate Investment Trust III (KBSR) opened Q1 2026 with total revenue of US$58.4 million and a basic EPS loss of US$0.08. This set the tone for another data heavy update that investors will be parsing closely. Over recent quarters, the REIT has reported revenue in a tight band between US$58.4 million and US$69.4 million, while basic EPS has ranged from a profit of US$0.13 to a loss of US$0.22. This gives a clear view of how top line stability contrasts with pressure further down the...
NYSE:ARX
NYSE:ARXInsurance

Accelerant Holdings Scales MGA Platform As AI Drives Fee-Based Growth

Accelerant Holdings (NYSE:ARX) is growing its specialty insurance platform, adding new member MGAs and drawing more third-party participants to its exchange. The company is rolling out artificial intelligence across operations, aiming to support fee-based revenue and improve efficiency. Recent developments also include strengthening leadership capacity as the business and partner network expand. Accelerant Holdings, trading at $15.44, is drawing attention as it scales its specialty...
NYSE:GPN
NYSE:GPNDiversified Financial

Global Payments AI POS Push Tests Restaurant Growth And Margin Story

Global Payments (NYSE:GPN) has introduced AI-powered handheld and kiosk point of sale devices for restaurants, unveiled at a major national trade show. The launch is paired with new research on how order anxiety affects quick service restaurant revenue and how technology can help address it. These products expand the Genius platform and embedded payments approach, supported by national advertising to reach restaurant operators at scale. Global Payments is rolling out this AI-focused push...
NasdaqGS:ALRM
NasdaqGS:ALRMSoftware

Is It Time To Reassess Alarm.com Holdings (ALRM) After The Recent Share Price Slump?

If you are wondering whether Alarm.com Holdings' current share price reflects its true worth, this breakdown will help you see how the stock stacks up against several valuation checks. The stock last closed at US$42.52, with the share price down 10.7% over the past week and down 28.7% over the past year. These moves may have changed how investors view its potential and risk. Recent coverage has focused on Alarm.com Holdings as part of broader discussions about software stocks and how...
NasdaqGS:APLS
NasdaqGS:APLSBiotechs

A Look At Apellis Pharmaceuticals (APLS) Valuation After The Biogen Acquisition Announcement

Why Apellis Pharmaceuticals (APLS) Is On Investors’ Radar Apellis Pharmaceuticals (APLS) has drawn fresh attention after being acquired by Biogen, with the company now operating as a subsidiary as of May 14, 2026, while its stock continues to trade independently. See our latest analysis for Apellis Pharmaceuticals. At a share price of US$41.03, Apellis has seen a sharp 90 day share price return of 89.08% and a 1 year total shareholder return of 135.13%. However, the 3 year total shareholder...
NYSE:APH
NYSE:APHElectronic

Amphenol Joins EBO Standard To Shape AI Data Center Connectivity

Amphenol (NYSE:APH) has joined a new multi source agreement to standardize expanded beam optical connectivity for AI data centers. The group includes 3M, AMD, Cisco, Meta and Arista Networks, collaborating on open, interoperable EBO specifications. The initiative targets next generation data center infrastructure used by hyperscale and enterprise customers. Amphenol is a large connector and interconnect systems supplier, with products that feed into data centers, communications, automotive...
NasdaqGS:FWON.K
NasdaqGS:FWON.KEntertainment

Is Formula One Group (FWON.K) Pricing Reflect Its Slowing Share Gains And Premium P/E?

Wondering if Formula One Group at around US$89.54 is priced fairly or if the market is missing something? This article looks at what the current valuation signals might be telling you. The stock is down about 5.2% over the past week and 1.0% over the past month, with returns also lower year to date at 8.7% and over the last year at 7.4%, even though the 3 year and 5 year returns sit at 26.4% and 108.4% respectively. Recent headlines around Formula One Group have kept attention on the long...
NYSE:ALH
NYSE:ALHMachinery

Is It Time To Reassess Alliance Laundry Holdings (ALH) After Its Recent Share Price Swings?

If you are wondering whether Alliance Laundry Holdings at around US$23.83 is priced attractively or not, you will want to look closely at what the valuation signals are really saying. The stock is up 11.4% year to date, even though it has fallen 6.2% over the last week and 4.7% over the past month, which suggests sentiment around the shares has been shifting over the short term. Recent coverage has focused on Alliance Laundry Holdings in the context of its listing and positioning within the...
NYSE:WCC
NYSE:WCCTrade Distributors

Is It Too Late To Consider WESCO International (WCC) After Its 109% One-Year Rally?

If you are wondering whether WESCO International stock still offers value after its strong run, the next sections will walk through what the current price might be implying. The stock closed at US$358.72, with returns of 1.0% over the past week, 17.3% over the past month, 42.3% year to date and 108.7% over the past year, plus very large gains over 3 and 5 years of 174.8% and 255.8% respectively. Those figures can change how you think about risk and reward today. Recent coverage has focused...
NasdaqGS:WGS
NasdaqGS:WGSHealthcare

GeneDx Fraud Probes And Guidance Cut Put Valuation Gap In Focus

GeneDx Holdings (NasdaqGS:WGS) reported a significant Q1 2026 revenue miss and sharply cut its full year guidance. Following this update, two law firms launched investigations into potential securities fraud linked to the company’s prior commentary on revenue and profitability. The investigations focus on whether recent statements were materially misleading, especially given the reaffirmation of optimistic targets shortly before the guidance change. These events came alongside a steep fall...
NYSE:GBX
NYSE:GBXMachinery

Toronto Dominion Takes 6% Passive Stake In Greenbrier As Valuation Stretches

The Toronto Dominion Bank and its affiliate TD Securities have disclosed a passive ownership stake of more than 6% in Greenbrier Companies. The position was reported in a Schedule 13G/A filing, indicating a sizeable institutional holding in NYSE:GBX common stock. The filing signals a meaningful change in Greenbrier Companies' shareholder base involving a large financial institution. For existing and potential shareholders, this new stake comes as NYSE:GBX trades at around $47.64, with the...
NYSE:BDC
NYSE:BDCElectronic

Belden’s RUCKUS Deal Recasts Growth Story In AI Ready Networking

Belden (NYSE:BDC) announced an agreement to acquire RUCKUS Networks for approximately US$1.85b. The deal is intended to position Belden as a provider of end to end IT and operational technology networking solutions. The transaction is expected to immediately affect Belden's financial profile, including margins and earnings. The acquisition expands Belden's reach into AI focused networking markets that the company views as high growth areas. Belden, known for its signal transmission and...
NYSE:ULS
NYSE:ULSProfessional Services

UL Solutions Scooter Warning Puts Safety Marks And Valuation In Focus

UL Solutions (NYSE:ULS) issued a public warning about certain electric scooters carrying unauthorized UL certification marks. The company said these scooters may pose safety risks for consumers and do not reflect its official testing or certification. The alert focuses attention on brand protection and the integrity of UL Solutions' safety marks across fast growing consumer electronics categories. For investors, this update relates directly to what UL Solutions sells: independent safety...
NasdaqGM:IVVD
NasdaqGM:IVVDBiotechs

Invivyd (IVVD) Q1 Loss Of US$41.4 Million Reinforces Bearish Unprofitability Narrative

Invivyd (IVVD) has released its Q1 2026 numbers with revenue of about US$13.7 million and a basic EPS loss of US$0.13, alongside a trailing 12 month net loss of US$77.6 million. The company has seen revenue move from US$25.4 million in Q4 2024 on a trailing 12 month basis to US$55.9 million in the latest trailing period, while trailing basic EPS has shifted from a loss of US$1.43 to a loss of US$0.35. Investors are therefore looking at a business where top line momentum is meeting still heavy...
NasdaqGS:TYRA
NasdaqGS:TYRABiotechs

Is Tyra Biosciences’ (TYRA) Dabogratinib 3×3 Focus Reframing Its Risk Reward Profile?

Tyra Biosciences, Inc. recently reported first-quarter 2026 results showing a wider net loss of US$39.31 million and basic loss per share of US$0.64, while highlighting progress across three Phase 2 trials for its lead candidate dabogratinib and a cash balance of US$383.5 million supporting operations into the second half of 2028. An interesting angle for investors is how Tyra’s “dabogratinib 3×3” plan concentrates resources on three FGFR3-driven indications, potentially shaping its future...
OTCPK:RLEA
OTCPK:RLEAAuto Components

Rubber Leaf (OTCPK:RLEA) Turns Q1 EPS Positive Yet Ongoing Losses Challenge Bullish Narratives

Rubber Leaf (OTCPK:RLEA) opened 2026 with Q1 revenue of about US$3.3 million and basic EPS of roughly US$0.01, with the stock trading around US$4.50. Over recent periods, the company has seen quarterly revenue range from US$0 to about US$3.3 million while basic EPS has moved between a loss of roughly US$0.01 and a gain of just under US$0.01. This gives investors a clear view of how sensitive margins have been to shifts in activity levels. See our full analysis for Rubber Leaf. With the...
NasdaqGM:GUTS
NasdaqGM:GUTSMedical Equipment

Fractyl Health (GUTS) Is Up 14.0% After RJVA-001 Human Trial Nod And Q1 Profitability Shift – Has The Bull Case Changed?

In May 2026, Fractyl Health reported first-quarter 2026 net income of US$9.22 million, reversing a prior-year loss, and secured authorization in the Netherlands to begin a Phase 1/2 first-in-human trial of RJVA-001, its Smart GLP-1 gene therapy candidate for type 2 diabetes. An important detail for investors is that this regulatory clearance makes Fractyl a dual clinical-stage company, advancing both its Revita procedure for post‑GLP‑1 weight maintenance and its Rejuva gene therapy platform...